INFLUENZA AND BIOTHREAT DIAGNOSTIC OPPORTUNITIES

Dr. John S. Lee, Ph.D.
October 19, 2016

Resilient People. Healthy Communities. A Nation Prepared.
Influenza Diagnostic Opportunities

- **Current Programs**
  - Point-of-Care Diagnostics
  - Flu Subtyping – Seasonal vs Novel/Non-Seasonal
  - Antiviral resistance
The Alere Influenza A & B assay

- Develop an easy to use, CLIA waived, FDA 510(k) cleared Point-of-Care (POC) device that has the ability to detect and differentiate seasonal and non-seasonal influenza A & B viruses
- Molecular assay: nested isothermal amplification, CLIA-waived for use in a physician’s office
- Rapid results <20 min
InDevR

- Developing a new, **multiplexed influenza diagnostic** termed FluChip-8G
  - *Multiplexed* analysis of viral genes within 4 hours
  - *Genotyping* the assay accurately identifies virus type and subtype, including B lineage (Yamagata or Victoria)
  - *Anti-viral susceptibility*
DNAe

- Develop, validate, and seek FDA clearance for a simplified Next Generation Nucleotide Sequencing Platform
  - Diagnostic identification of pandemic and seasonal influenza
- Pathogen Capture System (PCS)
- Bringing genomic diagnostics to the patient
  - delivering actionable results direct from blood
- Option for Antimicrobial resistance (AMR) testing
Becton, Dickinson and Company

- Neuraminidase-activity Chemiluminescent assay
- Detect Resistance to Neuraminidase Inhibitors
- Directly from clinical samples in less than 30 minutes
- Fills a gap that will improve antiviral monitoring

Substrate
(Hurt et al., Options IX Conference, 2016)
Areas of Interest - Influenza
BAA-16-100-SOL-0002 AOI #3

- 3.1 Specimen collection materials & methods
- 3.2 Sequencing methods – Clinical Lab
- 3.3 Antiviral drug resistant influenza virus detection
- 3.4 Prognostic marker(s) of influenza infection, both symptomatic and pre-symptomatic
- 3.5 Home use or point-of-care Influenza diagnostics tests
- 3.6 Studies to demonstrate the treatment impact of Influenza diagnostics
Biothreat Diagnostic Opportunities

- Current Programs
  - Zika Diagnostics and Blood Screening for Zika virus
  - Anthrax Diagnostics
  - Ebola Diagnostics
  - Burkholdaria Diagnostics
InBios

- Zika Detect IgM Capture ELISA
  - Detection of Zika IgM antibodies in human serum
  - Capture Format, utilizes CDC produced Virus Like Particles
  - Target engineered to reduce/eliminate cross-reactivity
  - 4-4.5 hours assay, no overnight incubation

- EUA issued 17SEP2016
- 510(k) Zika IgM
DiaSorin

- LIAISON ZIKA VIRUS IgM and IgG automated immunoassays
  - LIAISON® XL is a fully automated chemiluminescence analyzer, performing complete sample processing
  - EUA filing for Zika IgM/IgG ELISA
  - 510(k) Validation
OraSure – Ebola & Zika

- The OraQuick Ebola assay
  - Easy to use Lateral flow hand held device
  - CLIA-waived for use in a POC-field setting
  - Rapid results <30 min
  - Whole Blood or Oral Fluid Samples

- The OraQuick Zika assay
  - Easy to use Lateral flow hand held device
  - CLIA-waived for use in a POC field setting
  - Rapid results <30 min
  - Whole Blood, serum, plasma, Oral Fluid Samples, and possible semen and urine
  - EUA Zika Test for IgM WB
  - Feasibility assessment of IgM OF, IgM/IgG, and IgM/Ag prototypes
Chembio Diagnostic Systems, Inc.
Zika Diagnostics

- POC Zika Assay using the Dual Path Platform (DPP®) Technology
  - Easy to use Lateral flow hand held device
  - CLIA-waived for use in a POC or field setting
  - Rapid results <30 min
  - Whole Blood, serum, plasma
- EUA/510(k)/CLIA waiver – Zika IgM/IgG
Support the requirements of a Biologics License Application (BLA) of an investigational use blood screening assay – cobas® ZIKA for use with the cobas 6800/8800 system.
Hologic – Blood Screening

- To support and build GMP-level ZIKV assay reagents and conduct a pivotal clinical trial and BLA submission.
MRI Global

- MRI-Global - MRIGlobal Dx's mission is to enable the commercialization of diagnostics for improved patient outcomes. MRIGlobal Dx provides laboratory services for CLIA-certified laboratories and in vitro diagnostics developers.

- Develop an FDA cleared in vitro diagnostic assay for the detection of *Bacillus anthracis*, validated for use on the Applied Biosystems® 7500 Fast Dx
SRI International

- Anthrax Diagnostics
  - Development of a Rapid, Point-of-Care Anthrax Diagnostic Assay System for the protein targets specific for *B. anthracis*, including LF, LTx, and PGA.

- Burkholderia Diagnostics
  - Biomarker Characterization and Confirmation for Rapid Clinical Diagnosis of: *Burkholderia pseudomallei, Burkholderia mallei, and Yersinia pestis.*
First Light Biosciences

- Anthrax Diagnostics
  - Development of a Rapid, Point-of-Care Anthrax Diagnostic Assay System for the protein targets specific for *B. anthracis*, including LF, LTx, and PGA
  - Direct from blood
- Early in infection and to determine the correct antibiotic therapy – AMR testing
NanoMR (Acquired by DNAe)

- Pathogen Capture System (PCS)
  - 10 mL whole blood
  - automated workstation
  - concentrations as low as 1 CFU/mL.
- The final output of the PCS is a volume of purified pathogen DNA that can be used for downstream identification (ID) analysis
Areas of Interest - Biothreats
BAA-16-100-SOL-00001 AOI #6

- 6.4 Anthrax diagnostic assay system
- 6.5 Anthrax lateral flow Lethal Factor immunoassay - USG developed antibodies
- 6.6 Hardware platform development
- 6.7 Knowledge Development - “Bio-threat Agent of Interest”
- 6.9 Zika Virus Infection Diagnostics & Blood Screening